Parschauer Karah Herdman sold $47K of RARE

Parschauer Karah Herdman (EVP and Chief Legal Officer) sold 1,900 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $24.92 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parschauer Karah Herdman
Published Aug 4, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
high confidence
Mentioned
$RARE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value) by the EVP and Chief Legal Officer, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and modest dollar value suggest limited incremental trading edge.

03

What to watch

The sale size ($47.3k) is relatively small versus typical institutional flows, and the filing does not provide any new operational or financial guidance.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-04, transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc. (RARE).

Company-level read

Ticker impact

$RARENeutralHigh confidence
Context

Ultragenyx (RARE) disclosed an EVP and Chief Legal Officer open-market sale of 1,900 shares at $24.92 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

Form 4 insider sales are common and the filing explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with management caution, so traders may still watch for follow-on disclosures.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    RARE, the company that filed the Form 4 insider transaction.

  • Parschauer Karah Herdman

    EVP and Chief Legal Officer who sold 1,900 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.